Authors
Latest:
How Tax Reform Will Affect the Pharmaceutical IndustryThis article examines the key ways the new tax bill will impact the pharmaceutical industry.
Latest:
How to Build a Strategic Digital Health Function within BiopharmaKey takeaways on digital health from the 2021 JP Morgan Healthcare conference.
Latest:
The Analytics Revolution of 2018: Transforming Insights to ActionScott Beauchamp discussed the future of analytics in the life sciences industry-and look at how peers in other industries have reaped the benefits of being early movers.
Latest:
Why a Data Health Check May Be the Best Medicine for Pharmaceutical Regulatory ComplianceAdhering to new compliance legislation such as Identification of Medicinal Products (IDMP) can bring a pharma company benefits as well as challenges, writes Darren Cooper.
Latest:
Delivering Value from Data AnalyticsFor companies that overcome the challenges, there is tremendous opportunity to drive sustainable growth through technology and analytics-driven business innovation, writes Vita Cassese.
Latest:
The Personalized Genetic Profile: It’s Time to AlignInnovations in consumer genetic health are rapidly advancing-and pharma commercial thinking needs to catch up.
Latest:
The Personalized Genetic Profile: It’s Time to AlignInnovations in consumer genetic health are rapidly advancing-and pharma commercial thinking needs to catch up.
Latest:
Pricing Turning Point: The Case for Innovating Pharma’s ModelDrawing from implementation lessons and successes in other industries, possible strategy shifts to pharma’s pricing playbook are explored.
Latest:
Pricing Turning Point: The Case for Innovating Pharma’s ModelDrawing from implementation lessons and successes in other industries, possible strategy shifts to pharma’s pricing playbook are explored.
Latest:
Pharma Tech Trends for Today and TomorrowAdTech (Advertising Technology) and AI/ML (Artificial Intelligence/Machine Learning) are playing significant roles in transforming the healthcare industry, particularly in areas like digital marketing and clinical trials. Let's explore each area in more detail.
Latest:
Shining a Light on Supply Chain VisibilitySteve Cottrell assesses the risks of lapses in pharma's supply chain visibility and outlines what can be done to minimize them
Latest:
Transparent and Relevant Evaluations of Value: An Active Role for PharmaThe biopharma industry should embrace the developments about value assessment in the US and take a leading role in defining and demonstrating what can be considered credible and relevant cost-effectiveness studies, write Ross Maclean and Jeroen Jansen.
Latest:
Adaptive Pathways and Real-World Evidence: Three PerspectivesHighlights of last year's ISPOR European Congress panel debated on one of the key issues regarding patient access to transformative treatments: adaptive pathways and the application of real-world evidence.
Latest:
Doctors Are People Too: Communicating through EntertainmentIt’s just as hard to make treatments look good to physicians as it is patients-but communicating through entertainment can be done.
Latest:
Organizational Design and Talent Strategy in the Changing Biopharma LandscapeWithout considering the organizational and talent aspects of change, companies put themselves at risk for poor employee engagement, loss of talent, and ultimately, failed business initiatives, writes Viq Prevaaz.
Latest:
The New (Augmented) Reality in the Life SciencesThree ways AR can bolster pharma commercialization strategies.
Latest:
Post-Pandemic Physician Engagement: 4 Areas to Consider When Rethinking Your Sales Talent and Their ApproachCOVID-19 has been game-changing for pharma sales, driving demand for new models and reps with the right competencies and skills to succeed in a hybrid sales environment.
Latest:
Planning for Post-Deal IntegrationJo Pisani and Cynthia Chan outline the key legal considerations for post-deal integration.
Latest:
Moving Scientists from the Lab to the Executive SuiteThis op-ed discusses the varying skills that business leaders should look at in scientists when thinking about talent for the lab and the executive suite.
Latest:
Improving Persistence: Brand Team Dos and Don'tsIn Part 4 of a 4-part series on brand teams, this article discusses the tactics brand teams and partners should follow to improve medication and persistence.
Latest:
Next-Gen Patient Support Programs Gain Momentum in the Quest for ValueThere’s a growing realization that advances in connected devices, sensors and predictive analytics represent a game-changer when it comes to patient support programs (PSPs), writes Jim O'Donaghue.
Latest:
3 Behavioral Biases that Stunt the Potential of MarketersAs marketers mine for insights, they need to be keenly aware of the behavioral biases that can undermine their efforts, writes Kunsan Kim.
Latest:
Organizational Design and Talent Strategy in the Changing Biopharma LandscapeWithout considering the organizational and talent aspects of change, companies put themselves at risk for poor employee engagement, loss of talent, and ultimately, failed business initiatives, writes Viq Prevaaz.
Latest:
Atopic Dermatitis — Going Beyond the PillThere is a real opportunity for pharma to support the under-served population of atopic dermatitis patients, writes Mariel Metcalfe.
Latest:
Medical Affairs’ Search for MeaningThe need to look beyond the function’s traditional performance measures to the one that really matters-patient outcomes.
